The results of the phase 3 controlled and randomized study of the BBV152 anti COVID-19 vaccine made entirely in India have been published in the Lancet. It is a traditional adenovirus vaccine that has the advantage of being stored at temperatures of up to 8 degrees.
25,798 participants randomized to the vaccine or placebo were enrolled: the vaccine had an efficacy of 77.8% with respect to the onset of COVID-19 and 93.4% with respect to severe forms of the disease, with no particular reports of adverse reactions. The efficacy against the Delta variant was 65.2%.
As per authors, “BBV152 was highly efficacious against laboratory-confirmed symptomatic COVID-19 disease in adults. Vaccination was well tolerated with no safety concerns raised in this interim analysis, no anaphylactic events after BBV152 administration were reported, and all adverse events (solicited, unsolicited, and serious adverse events) were well balanced between the BBV152 and placebo groups”
Reference:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02000-6/fulltext
Leave a Reply